Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Cribriform amplatzer device closure of fenestrated atrial septal defects: Feasibility and technical aspects
Pediatric Cardiology, Volume 29, No. 3, Year 2008
Notification
URL copied to clipboard!
Description
Fenestrated atrial septal defects (F-ASDs) may pose a challenge to device closure; recently, a cribriform device with a minimal connecting intrawaist diameter and large, equal left- and right-sided discs has been designed to cover more than one adjacent defect. This study demonstrates the feasibility and technical aspects of closing F-ASDs using this new device. Sixteen patients between August 2003 and January 2006 were included in this study. The inclusion criterion was the presence of a F-ASD diagnosed by transesophageal echocardiography. One of the three available cribriform ASD device sizes (18, 25, or 35 mm) was implanted. Patients were followed for at least 1 year after the procedure. Thirteen patients had successful cribriform ASD device implantation (median age and weight, 12.5 years and 36 kg, respectively). Ten patients (62%) had an associated atrial septal aneurysm. The mean procedure time was 75.6 ± 28.5 min and the mean fluoroscopy time 14.8 ± 6.3 min. The RVEDD was significantly reduced, from a mean of 24.2 mm to 21.0 (p < 0.05). One patient developed atrial tachycardia requiring cardioversion during the procedure. There were no embolic events, heart block, or mortality. Complete closure was 10 of 13 (77 %) the next day and 12 of 13 (92%) at 6 and 12 months. We conclude that the cribriform Amplatzer device can be successfully and safely used in patients with F-ASDs. Complete closure may take up to 6 months. © 2007 Springer Science+Business Media, LLC.
Authors & Co-Authors
Numan, Mohammed T.
Qatar, Doha
Hamad Medical Corporation
El-Sisi, Amal Mahmoud
Qatar, Doha
Hamad Medical Corporation
Tofeig, Magdi
United Kingdom, Leicester
Glenfield Hospital
Gendi, Salwa
Qatar, Doha
Hamad Medical Corporation
Tohami, Tohami
Qatar, Doha
Hamad Medical Corporation
El-Said, Howaida Galal
Qatar, Doha
Hamad Medical Corporation
Egypt, Giza
Cairo University
Statistics
Citations: 29
Authors: 6
Affiliations: 3
Identifiers
Doi:
10.1007/s00246-007-9079-x
ISSN:
01720643
Research Areas
Health System And Policy